Delving into the Latest Updates on Chlorpheniramine Maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-(p-chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane, 1-(p-chlorophenyl)-1-(2-pyridyl)-3-N,N-dimethylpropylamine, 2-[p-chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine

+ [45]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCardiovascular Diseases+ [4]

Active Indication

Oedema vascularAngioedemaEczema+ [8]

Inactive Indication

Cutaneous hypersensitivityNeurodermatitisPhotosensitivity Disorders+ [1]

Originator Organization

Schering Plough A/S

Active Organization

Tianjin Lisheng Pharmaceutical Co., Ltd.

Fuji Yakuhin Co., Ltd.

Alfresa Pharma Corp.

+ [8]

Inactive Organization

Hubei Huazhong Pharmaceutical Co. Ltd.

Schering AG

Drug Highest PhaseApproved

First Approval Date

US (13 Jul 1949),

Urticaria

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC20H23ClN2O4

InChIKeyDBAKFASWICGISY-BTJKTKAUSA-N

CAS Registry113-92-8

The goal of this clinical trial is to learn about voice function before and 3 hours after administration of first generation over-the-counter antihistamine in individuals who have been medically diagnosed with allergies and routinely take over-the-counter (OTC) antihistamines for allergy symptoms. The main questions are:
Do first generation OTC antihistamines make voice function worse as measured via voice acoustic and aerodynamic measures? It is hypothesized that all objectives measures will reflect a negative change in voice function.
Do first generation OTC antihistamines make voice function worse as measured via participant and researcher perceptual measures? It is hypothesized that participants will rate their vocal function as more effortful after taking the antihistamine and researchers will rate voice quality as worse.
Participants ages 18-35 who have been diagnosed with allergies, are free of laryngeal pathology, and meet inclusion criteria will be consented. Participation in the study involves a pretrial visit and one day of data collection. The initial visit will obtain informed consent and train the trial measures. The 2nd day involves determination of systemic hydration (<1.02 g/ml), administration of the OTC antihistamine (Chlor-Trimeton), and measures taken at baseline and 3 hours after antihistamine administration. This antihistamine was selected for its lower sedation and anticholinergic effects than its other first-generation options. Each participant will take one, 12mg tablet. Onset action time for this antihistamine is 3 hours. Participants will be given water to consume during the 3 hour wait for the 2nd data time point to maintain hydration. Measures include routine clinical perceptual, acoustic, aerodynamic, and laryngeal imaging measures.

Start Date13 Jun 2023

Sponsor / Collaborator

Auburn University

NCT05886829 / CompletedPhase 2/3

A Multicentric, Randomized, Double-Blind, Comparative, Prospective, Placebo-controlled, Phase-II/III Clinical Trial (ACCROS-III)

The goal of this clinical trial is to examine the effectiveness of intranasal-administered Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for COVID-19. The main questions it aims to answer are:
To assess the efficacy of nasal spray with Chlorpheniramine (0.4%) for improving clinical recovery in COVID-19 patients.
To assess the efficacy, safety, and tolerability of nasal spray with Chlorpheniramine (0.4%) as an adjunct to the standard of care in reducing hospitalizations and improving clinical recovery in adult patients with mild COVID-19.

Start Date27 Jul 2022

Sponsor / Collaborator

FERRER MEDICAL INNOVATIONS LLCStartup

100 Clinical Results associated with Chlorpheniramine Maleate

Login to view more data

100 Translational Medicine associated with Chlorpheniramine Maleate

Login to view more data

100 Patents (Medical) associated with Chlorpheniramine Maleate

Login to view more data

2,429

Literatures (Medical) associated with Chlorpheniramine Maleate

01 Jul 2024·Current reviews in clinical and experimental pharmacology

Chlorpheniramine, an Old Drug with New Potential Clinical Applications: A Comprehensive Review of the Literature

Review

Author: Sanchez-Gonzalez, Marcos A. ; Khawaja, Uzzam A. ; Ferrer, Gustavo ; Rizvi, Syed A.A.

Abstract::

Chlorpheniramine Maleate (CPM), also known as chlorphenamine, is a potent alkylamine first-generation H1 antihistamine that has been used since the 1950s. CPM is a widely popular drug commonly used to treat allergic conditions, given its antihistamine properties. Although mainly used in over-the-counter treatment for cough and colds, various studies discuss a wide range of CPM's clinical uses, such as treating asthma, plasma cell gingivitis, chronic urticaria, and depression, among others. This antihistamine is usually taken orally; however, intravenous, intramuscular, and subcutaneous routes have been documented. Intranasal routes of this drug have recently been explored, especially due to its antiviral properties against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Accordingly, given CPM's extensive medical and safety profile, the present review explores this versatile drug's current and potential clinical applications. Although it is widely used mainly for treating common colds and aforementioned allergic conditions, CPM can be used for other clinical indications. The repurposing of CPM for other clinical indications, such as COVID-19, needs to be further explored through more extensive studies.

01 Mar 2024·Toxicon: X

Rhabdomyolysis due to unidentified jellyfish envenomation in west Malaysian waters

Author: Arumugam, Tilagavahti ; Khoo, Chyi Chyi ; Ismail, Ahmad Khaldun ; Loy, Jia Shyi ; Ngian, Geok Hoon

Jellyfish envenomation is a common marine injury. We report a case of a 9-year-old boy who developed muscle weakness and rhabdomyolysis after a jellyfish sting. He was stung on the face, hands, and feet. He sustained immediate pain and numbness; however no immediate action was taken. He was taken to a primary health clinic and discharged with syrup Paracetamol 15mg/kg/dose and syrup Chlorpheniramine maleate 0.1mg/kg/dose for symptomatic relief. Over the next several days, the pain became generalized involving upper and lower limbs, aggravated by movement, and not alleviated by analgesia nor antihistamine. His condition worsened with the development of weakness of upper and lower limbs and 'tea-colored' urine from day 3 of illness. He received treatment for rhabdomyolysis at a district hospital. Maintaining hydration and urine output and symptomatic relief are central to treatment. His muscle pain and weakness improved. He was discharged well and remained asymptomatic at follow up.

01 Jan 2024·Heliyon

Are polypharmacy side effects predicted by public data still valid in real-world data?

Article

Author: Kim, Kyuwoong ; Kang, Hee Jun ; Cho, Ha Na ; Kim, Minkyoung ; Kim, Young-Hak ; Seo, Hyeram ; Choi, Heejung ; Park, Seohyun ; Gwon, Hansle ; Kim, Yunha ; Ahn, Imjin ; Kee, Gaeun ; Han, JiYe ; Jun, Tae Joon

Background and Objective:

Although interest in predicting drug-drug interactions is growing, many predictions are not verified by real-world data. This study aimed to confirm whether predicted polypharmacy side effects using public data also occur in data from actual patients.

Methods:

We utilized a deep learning-based polypharmacy side effects prediction model to identify cefpodoxime-chlorpheniramine-lung edema combination with a high prediction score and a significant patient population. The retrospective study analyzed patients over 18 years old who were admitted to the Asan medical center between January 2000 and December 2020 and took cefpodoxime or chlorpheniramine orally. The three groups, cefpodoxime-treated, chlorpheniramine-treated, and cefpodoxime & chlorpheniramine-treated were compared using inverse probability of treatment weighting (IPTW) to balance them. Differences between the three groups were analyzed using the Kaplan-Meier method and Cox proportional hazards model.

Results:

The study population comprised 54,043 patients with a history of taking cefpodoxime, 203,897 patients with a history of taking chlorpheniramine, and 1,628 patients with a history of taking cefpodoxime and chlorpheniramine simultaneously. After adjustment, the 1-year cumulative incidence of lung edema in the patient group that took cefpodoxime and chlorpheniramine simultaneously was significantly higher than in the patient groups that took cefpodoxime or chlorpheniramine only (p=0.001). Patients taking cefpodoxime and chlorpheniramine together had an increased risk of lung edema compared to those taking cefpodoxime alone [hazard ratio (HR) 2.10, 95% CI 1.26-3.52, p<0.005] and those taking chlorpheniramine alone, which also increased the risk of lung edema (HR 1.64, 95% CI 0.99-2.69, p=0.05).

Conclusions:

Validation of polypharmacy side effect predictions with real-world data can aid patient and clinician decision-making before conducting randomized controlled trials. Simultaneous use of cefpodoxime and chlorpheniramine was associated with a higher long-term risk of lung edema compared to the use of cefpodoxime or chlorpheniramine alone.

1

News (Medical) associated with Chlorpheniramine Maleate

06 Sep 2023

·www.biospace.com

Dr. Ferrer Biopharma to Showcase Groundbreaking Research in Post-COVID Treatment at ERS Congress 2023

Intranasal Chlorpheniramine Shows Significant Promise in Mitigating Prolonged Post-COVID-19 Symptoms HALLANDALE BEACH, Fla.--(BUSINESS WIRE)-- Leading pharmaceutical research and development company Dr. Ferrer Biopharma proudly announces its participation in the highly anticipated European Respiratory Society (ERS) Congress 2023, scheduled in Milan, Italy, from September 9th to 13th. During the event, the company will present late-breaking findings from two randomized controlled trials that shed light on the potential of intranasal Chlorpheniramine to treat post-COVID-19 long-term symptoms. The ERS Congress serves as a premier platform in respiratory health, featuring the latest advancements in clinical care, scientific research, education, and technology, where experts and researchers worldwide share insights and discoveries, driving progress in respiratory medicine. Highlighting a pioneering study, the late-breaking abstract by Dr. Ferrer Biopharma introduces Intranasal Chlorpheniramine Maleate (iCPM) as an innovative therapeutic strategy with promising anti-inflammatory and antiviral properties against COVID-19 and respiratory viruses, specifically addressing long-term symptoms. Investigating the effects of this novel approach, Dr. Ferrer Biopharma's presentation delves into the impact of intranasal Chlorpheniramine on post-COVID-19 symptoms, revealing significant improvements in clinical recovery time and alleviation of symptoms like anosmia, ageusia, and cough, as demonstrated by the two randomized trials ACCROS I, and ACCROS III. The subsequent post-trial follow-up highlights Chlorpheniramine's remarkable reduction of post-COVID symptoms by over 90% compared to a placebo. "The antiviral and anti-inflammatory effect of iCPM can explain the significant impact in reducing time to clinical recovery in the acute illness," said Dr. Franck Rahaghi, Clinical Professor of Medicine and chairman of Cleveland Clinic Florida pulmonary and critical care department, who leads the study. "iCPM may have better impact in reducing long-COVID symptoms. This reformulated treatment could become a cornerstone intervention in addressing the dreaded issue of long-COVID." "We are excited to unveil the results of our comprehensive research that explores the impact of intranasal chlorpheniramine on post-COVID-19 long-term symptoms," said Dr. Fernando Valerio, Principal Investigator. The company's participation underscores its dedication to propelling innovation and achieving excellence in respiratory medicine. About Dr. Ferrer Biopharma: Dr. Ferrer Biopharma is a pioneering pharmaceutical research and development company dedicated to advancing intranasal medications for treating cough, colds, flu, and allergies. We use advanced technology to bring to the market high-quality, evidence-based, consumer-focused therapies that originated at the bedside. For more information, please visit DrFerrerBioPharma.com.

Clinical Study

100 Deals associated with Chlorpheniramine Maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Chlorpheniramine Maleate	R06AB04	DB01114

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Oedema vascular	JP	Fuso Pharmaceutical Industries Ltd.	31 Aug 2007
Angioedema	JP	Kowa Corp.	20 Jul 1984
Eczema	JP	Alfresa Pharma Corp.	24 Apr 1984
Rhinitis, Allergic	JP	Alfresa Pharma Corp.	24 Apr 1984
Drug Eruptions	CN	Grand Pharmaceutical Group	01 Jan 1981
Drug Eruptions	CN	Tianjin Huajin Pharmaceutical Co. Ltd.	01 Jan 1981
Drug Eruptions	CN	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Drug Eruptions	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Drug Eruptions	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Edema	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Pruritus	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Rhinitis, Allergic, Seasonal	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Rhinitis, Vasomotor	JP	Nichi-Iko Pharmaceutical Co., Ltd.	27 Jan 1961
Urticaria	US	Schering AG	13 Jul 1949

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	HN	FERRER MEDICAL INNOVATIONS LLCStartup	27 Jul 2022
Cutaneous hypersensitivity	Phase 1	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Neurodermatitis	Phase 1	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Photosensitivity Disorders	Phase 1	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019
Pruritis (itchy skin)	Phase 1	CN	Hubei Huazhong Pharmaceutical Co. Ltd.	19 Feb 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02073097 (CTgov)	Phase 1/2	Diffuse Large B-Cell Lymphoma	48	Pegfilgrastim+Acyclovir+carfilzomib+cyclophosphamide+Prednisone+doxorubicin hydrochloride+Vincristine sulfate+Rituximab	nvmhvynlex(ququxnvknj) = xyfggoqjtv fgqbmgecle (jjusknpyat, lsszetqnza - gvsgdyijod) View more	-	29 May 2024
NCT00538031 (CTgov)	Phase 2	Recurrent ovarian cancer \| Recurrent Primary Peritoneal Carcinoma \| Peritoneal Neoplasms ... View more	52	Cyclophosphamide (Arm I (Cyclophosphamide Alone))	ijlbyeevvq(htqhpjsept) = xbsgapmgkm orswwrqcur (liunlbxzun, cqndidectn - uqjshqrxja) View more	-	21 Apr 2023
				Cyclophosphamide+Celecoxib (Arm II (Cyclophosphamide + Celecoxib))	ijlbyeevvq(htqhpjsept) = hsetgcdwzh orswwrqcur (liunlbxzun, dnrkvsfwsl - kayfdgnxmv) View more
NCT01775475 (CTgov)	Phase 2	AIDS-Related Lymphoma \| AIDS-Related Diffuse Large Cell Lymphoma \| Immunoblastic Large-Cell Lymphoma	7	laboratory biomarker analysis+cyclophosphamide+prednisone+doxorubicin hydrochloride+vincristine sulfate (Arm I (CHOP))	jhxmaucvxx(zwvcsmntbq) = pvxihindzn utlvzeqbqa (dazuhzuxne, dptnbrgxjq - nlgbjkrsbg) View more	-	10 Oct 2022
				laboratory biomarker analysis+etoposide+cyclophosphamide+lomustine+procarbazine hydrochloride (Arm II (Oral Chemotherapy))	jhxmaucvxx(zwvcsmntbq) = dmklzqnzcl utlvzeqbqa (dazuhzuxne, josohtxhip - jnbylsbsub) View more
KCT0004880 (Pubmed \| J Anesth)	Not Applicable	Bladder Cancer	-	Chlorpheniramine group	yqkpbfoxif(yqkuwsdwum) = xghqxwxqjm aroulnbvbb (rwoyluidak )	Positive	10 Jul 2021
				Control group	yqkpbfoxif(yqkuwsdwum) = leusojtxev aroulnbvbb (rwoyluidak )
NCT00490529 (phase I/II, CTgov)	Phase 2	Mantle-Cell Lymphoma	59	Autologous hematopoietic stem cell transplant (HSCT)+PF-3512676+CYCLOPHOSPHAMIDE+Filgrastim+CpG-MCL vaccine+Rituximab	jnpsryfywl(xhpxppyyqr) = isnnnlwjig padihdnizr (pstdqjlxnh, hyggtpqpxv - ogohqsvsnt) View more	-	13 Jan 2020
NCT01959490 (CTgov)	Phase 2	Breast Cancer 3 \| Advanced breast cancer	16	Trastuzumab+CARBOPLATIN+Docetaxel+pertuzumab (Cohort 1P (HER2 Positive))	gfcvpgtndv(zglkapgxhr) = mcnkhgvtxj rgxqzmqfln (kdzwgjywnv, ijwkpohntt - ueejxldqps) View more	-	05 Mar 2019
				Trastuzumab+CARBOPLATIN+Docetaxel+pertuzumab (Cohort 1T (HER2 Positive))	gfcvpgtndv(zglkapgxhr) = bgzrvxdkbl rgxqzmqfln (kdzwgjywnv, tjxamxobwo - zhkhuqypbw) View more
NCT01093586 (CTgov)	Phase 2	Marginal zone lymphoma recurrent \| Recurrent Adult Grade III Lymphomatoid Granulomatosis \| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ... View more	14	allogeneic hematopoietic stem cell transplantation+cyclosporine+methylprednisolone+Busulfan+Cyclophosphamide+mycophenolate mofetil	xfjdgnqwbz(byjxsnoboc) = bcojpaqjhw hrgvpiptwx (powzxxgtjs, bniddnhflq - nenmytkgdc) View more	-	04 Jan 2019
NCT00849251 (CTgov)	Phase 1/2	Multiple Myeloma	31	CYCLOPHOSPHAMIDE+pegylated liposomal doxorubicin hydrochloride+bortezomib+Dexamethasone	ehgyhiubae(qwpjadyyqs) = rjhyjcddvh btaubcdugn (xytmmglvgb, jumyzpifio - soyjiaxfll) View more	-	08 Sep 2017
NCT00407888 (CTgov)	Phase 2	HER2 Positive Breast Cancer \| Metastatic breast cancer \| Estrogen receptor positive breast cancer ... View more	60	laboratory biomarker analysis+Trastuzumab+paclitaxel albumin-stabilized nanoparticle formulation+CYCLOPHOSPHAMIDE+Filgrastim+doxorubicin hydrochloride	wiazlwzvhm(jlyikqloho) = havzgigxja jyjsialmfe (pvvsgbjzwa, iaafmkxytf - behhqznxzz) View more	-	31 Aug 2017
NCT00343863 (CTgov)	Not Applicable	Male Breast Neoplasms \| Nausea and vomiting \| Nausea ... View more	41	Ondansetron+Dexamethasone (Dexamethasone + Ondansetron IV)	ummcknycju(riudoiukvo) = hyodllacxg umbzhitrzn (dgmvrwiymg, jhllgalltx - mbwzbuqmzo) View more	-	11 Jul 2017
				Palonosetron+Dexamethasone (Dexamethasone + Palonosetron IV)	ummcknycju(riudoiukvo) = jqiboznnwe umbzhitrzn (dgmvrwiymg, enagdvmthd - hvaareeuwd) View more